Np mrd loader

Record Information
Version1.0
Created at2021-06-21 00:36:21 UTC
Updated at2021-06-30 00:18:36 UTC
NP-MRD IDNP0043112
Secondary Accession NumbersNone
Natural Product Identification
Common Namelancifonin A
Provided ByJEOL DatabaseJEOL Logo
Description(1S,2R,6R,9S,11S,12R,14S,16S,19R)-1,14-dihydroxy-8,8,16-trimethyl-16-[(2R)-2-{[(2E)-4-methyl-5-oxo-2,5-dihydrofuran-2-ylidene]methyl}propanoyl]-3,7,20,21-tetraoxahexacyclo[9.8.1.1¹⁴,¹⁹.0²,⁶.0²,⁹.0¹²,¹⁹]Henicosane-4,13-dione belongs to the class of organic compounds known as furopyrans. These are organic polycyclic compounds containing a furan ring fused to a pyran ring. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom. Pyran a six-membered heterocyclic, non-aromatic ring, made up of five carbon atoms and one oxygen atom and containing two double bonds. lancifonin A is found in Schisandra lancifolia. It was first documented in 2002 (PMID: 33651529). Based on a literature review very few articles have been published on (1S,2R,6R,9S,11S,12R,14S,16S,19R)-1,14-dihydroxy-8,8,16-trimethyl-16-[(2R)-2-{[(2E)-4-methyl-5-oxo-2,5-dihydrofuran-2-ylidene]methyl}propanoyl]-3,7,20,21-tetraoxahexacyclo[9.8.1.1¹⁴,¹⁹.0²,⁶.0²,⁹.0¹²,¹⁹]Henicosane-4,13-dione (PMID: 33079503) (PMID: 26389513) (PMID: 26389498) (PMID: 26389454) (PMID: 26389451) (PMID: 26389436).
Structure
Thumb
SynonymsNot Available
Chemical FormulaC29H34O11
Average Mass558.5800 Da
Monoisotopic Mass558.21011 Da
IUPAC Name(1S,2R,6R,9S,11S,12R,14S,16S,19R)-1,14-dihydroxy-8,8,16-trimethyl-16-[(2R)-2-{[(2E)-4-methyl-5-oxo-2,5-dihydrofuran-2-ylidene]methyl}propanoyl]-3,7,20,21-tetraoxahexacyclo[9.8.1.1^{14,19}.0^{2,6}.0^{2,9}.0^{12,19}]henicosane-4,13-dione
Traditional Name(1S,2R,6R,9S,11S,12R,14S,16S,19R)-1,14-dihydroxy-8,8,16-trimethyl-16-[(2R)-2-{[(2E)-4-methyl-5-oxofuran-2-ylidene]methyl}propanoyl]-3,7,20,21-tetraoxahexacyclo[9.8.1.1^{14,19}.0^{2,6}.0^{2,9}.0^{12,19}]henicosane-4,13-dione
CAS Registry NumberNot Available
SMILES
[H]O[C@]12O[C@]3(C([H])([H])C([H])([H])[C@@](C(=O)[C@@]([H])(C(\[H])=C4\OC(=O)C(=C4[H])C([H])([H])[H])C([H])([H])[H])(C([H])([H])[H])C1([H])[H])[C@]([H])(C2=O)[C@@]1([H])O[C@]3(O[H])[C@]23OC(=O)C([H])([H])[C@@]2([H])OC(C([H])([H])[H])(C([H])([H])[H])[C@]3([H])C1([H])[H]
InChI Identifier
InChI=1S/C29H34O11/c1-13(8-15-9-14(2)23(33)36-15)21(31)25(5)6-7-26-20(22(32)27(34,12-25)40-26)16-10-17-24(3,4)38-18-11-19(30)39-28(17,18)29(26,35)37-16/h8-9,13,16-18,20,34-35H,6-7,10-12H2,1-5H3/b15-8+/t13-,16+,17+,18-,20+,25+,26-,27+,28-,29+/m1/s1
InChI KeyBJXLGPZZSAECJW-MAIZYXLRSA-N
Experimental Spectra
Spectrum TypeDescriptionDepositor EmailDepositor OrganizationDepositorDeposition DateView
1D NMR13C NMR Spectrum (1D, 500 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 500 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 100 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 100 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 200 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 200 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 300 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 300 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 400 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 400 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 600 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 600 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 700 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 700 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 800 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 800 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 900 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 900 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 1000 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 1000 MHz, acetone-d6, simulated)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
Predicted Spectra
Not Available
Chemical Shift Submissions
Not Available
Species
Species of Origin
Species NameSourceReference
Schisandra lancifoliaJEOL database
    • Shi, Y.-M., et al, Org. Lett. 16, 1370 (2014)
Chemical Taxonomy
Description Belongs to the class of organic compounds known as furopyrans. These are organic polycyclic compounds containing a furan ring fused to a pyran ring. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom. Pyran a six-membered heterocyclic, non-aromatic ring, made up of five carbon atoms and one oxygen atom and containing two double bonds.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassFuropyrans
Sub ClassNot Available
Direct ParentFuropyrans
Alternative Parents
Substituents
  • Furopyran
  • Furofuran
  • Oxepane
  • 2-furanone
  • Dicarboxylic acid or derivatives
  • 3-furanone
  • Gamma butyrolactone
  • Monosaccharide
  • Oxane
  • Pyran
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Tetrahydrofuran
  • Cyclic alcohol
  • Furan
  • Dihydrofuran
  • Enol ester
  • Carboxylic acid ester
  • Lactone
  • Ketone
  • Hemiacetal
  • Oxacycle
  • Carboxylic acid derivative
  • Dialkyl ether
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organic oxygen compound
  • Carbonyl group
  • Organic oxide
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available
Physical Properties
StateNot Available
Experimental Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Predicted Properties
PropertyValueSource
logP1.52ALOGPS
logP2.57ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)9.22ChemAxon
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area154.89 ŲChemAxon
Rotatable Bond Count3ChemAxon
Refractivity135.45 m³·mol⁻¹ChemAxon
Polarizability53.81 ųChemAxon
Number of Rings7ChemAxon
BioavailabilityYesChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
HMDB IDNot Available
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FoodDB IDNot Available
KNApSAcK IDNot Available
Chemspider IDNot Available
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem Compound139042059
PDB IDNot Available
ChEBI IDNot Available
Good Scents IDNot Available
References
General References
  1. Authors unspecified: Curcumin (Curcuma, Turmeric) and Cancer (PDQ(R)): Health Professional Version. 2002. [PubMed:33651529 ]
  2. Authors unspecified: Cancer Therapy Interactions With Foods and Dietary Supplements (PDQ(R)): Health Professional Version. 2002. [PubMed:33079503 ]
  3. Authors unspecified: Planning the Transition to End-of-Life Care in Advanced Cancer (PDQ(R)): Health Professional Version. 2002. [PubMed:26389513 ]
  4. Authors unspecified: Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ(R)): Health Professional Version. 2002. [PubMed:26389498 ]
  5. Authors unspecified: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ(R)): Health Professional Version. 2002. [PubMed:26389454 ]
  6. Authors unspecified: Cancer Prevention Overview (PDQ(R)): Health Professional Version. 2002. [PubMed:26389451 ]
  7. Authors unspecified: Spirituality in Cancer Care (PDQ(R)): Health Professional Version. 2002. [PubMed:26389436 ]
  8. Authors unspecified: Oral Cavity, Oropharyngeal, Hypopharyngeal, and Laryngeal Cancer Prevention (PDQ(R)): Health Professional Version. 2002. [PubMed:26389416 ]
  9. Authors unspecified: Adjustment to Cancer: Anxiety and Distress (PDQ(R)): Health Professional Version. 2002. [PubMed:26389397 ]
  10. Authors unspecified: Cancer Pain (PDQ(R)): Health Professional Version. 2002. [PubMed:26389387 ]
  11. Authors unspecified: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ(R)): Health Professional Version. 2002. [PubMed:26389336 ]
  12. Authors unspecified: Informal Caregivers in Cancer: Roles, Burden, and Support (PDQ(R)): Health Professional Version. 2002. [PubMed:26389284 ]
  13. Authors unspecified: Neuroblastoma Treatment (PDQ(R)): Patient Version. 2002. [PubMed:26389278 ]
  14. Authors unspecified: Late Effects of Treatment for Childhood Cancer (PDQ(R)): Health Professional Version. 2002. [PubMed:26389273 ]
  15. Authors unspecified: Lip and Oral Cavity Cancer Treatment (Adult) (PDQ(R)): Health Professional Version. 2002. [PubMed:26389262 ]
  16. Shi, Y.-M., et al. (2014). Shi, Y.-M., et al, Org. Lett. 16, 1370 (2014). Org. Lett..